Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Epic Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$3,535,020

408 payments

Through program year 2025, Epic Clinical Research is reported as receiving $3,535,020 in research payments, across 408 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $458,906 322
2024 Research $1,790,552 64
2023 Research $867,159 18
2022 Research $418,404 4

Breakdown

Who paid Research payments · program years 2022–2025
  1. Braintree Laboratories, Inc. $1,370,231 44 payments
  2. Moderna TX, Inc. $870,273 25 payments
  3. Merck Sharp & Dohme Corporation $710,839 8 payments
  4. Boehringer Ingelheim International GmbH $368,668 318 payments
  5. Novartis Pharmaceuticals Corporation $114,860 6 payments
  6. Amgen Inc. $60,724 2 payments
  7. Biogen, Inc. $21,065 1 payment
  8. Pfizer Inc. $10,900 1 payment
  9. Boehringer Ingelheim Pharma GmbH & Co.KG $6,677 1 payment
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $783 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $1,370,231 44 payments
  2. A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older $855,773 21 payments
  3. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na Adults $706,207 6 payments
  4. A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $317,979 295 payments
  5. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $76,848 3 payments
  6. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $51,025 1 payment
  7. A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi $34,311 1 payment
  8. A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) $21,065 1 payment
  9. BI 456906 in NASH F4 - pivotal trial $20,968 2 payments
  10. BI 456906 in NASH F2/F3 - pivotal trial $20,968 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record